|
|
Upfront Briefing
Revolution Medicines delivered one of the clearest oncology tape-movers of the day, posting Phase 3 pancreatic cancer survival data that reset expectations for the RAS(ON) field.
Elsewhere, Travere secured the first FDA approval for FSGS, while Regeneron used a new Telix radiopharma pact to expand its oncology toolkit. Clinical proof, label expansion and external pipeline building all moved today.
Tape Action
| Instrument |
Last close |
1D % |
YTD % |
| S&P 500 |
6,886.2 |
+1.0% |
+0.6% |
| Nasdaq 100 |
25,383.7 |
+1.1% |
+0.5% |
| Russell 2000 |
2,670.5 |
+1.5% |
+7.6% |
| Healthcare (XLV) |
148.0 |
+0.4% |
(4.5%) |
| Biotech (XBI) |
132.1 |
+2.0% |
+8.3% |
| Nasdaq Biotech (NBI) |
5,948.8 |
+1.7% |
+2.6% |
| Clinical Trials (BBC) |
44.5 |
+2.4% |
+12.6% |
|
- Risk appetite improved into the close as investors leaned on hopes the U.S.-Iran shock would stay contained; oil finished off session highs and broad equities recovered from an early geopolitical wobble.
- Biotech beta led that rebound: XBI +2.0% and NBI +1.7% outpaced both the S&P 500 +1.0% and Healthcare (XLV) +0.4%, pointing to renewed appetite for higher-duration growth rather than a purely defensive healthcare bid.
- Standout mover: Clinical Trials (BBC) rose +2.4%, consistent with investors pushing further down the risk curve into earlier-stage development exposure as software/AI and small-cap beta also strengthened.
- Market data: U.S. close Mon 13-Apr-2026.
The Big 3
|
1
|
Revolution Medicines posts standout Phase 3 pancreatic cancer data
|
- Revolution Medicines said daraxonrasib met the primary endpoint in the pivotal Phase 3 RASolute 302 trial in previously treated metastatic pancreatic cancer, with median overall survival of 13.2 months versus 6.7 months for chemotherapy and a 60% reduction in risk of death.
- Why it matters: This is not just another targeted-oncology data point. A clean overall survival win in metastatic pancreatic cancer is rare, commercially meaningful and potentially practice-changing. For investors, it sharpens the case that RAS(ON) inhibition can deliver beyond mechanism enthusiasm into registrational, category-defining outcomes — and raises the bar for competing KRAS and pan-RAS programs.
- Source: Company PR / BioSpace
- More: BioWorld
|
|
2
|
Travere wins first FDA approval for FSGS with FILSPARI
|
- Travere said FDA approved FILSPARI (sparsentan) to reduce proteinuria in adults and children aged 8 years and older with focal segmental glomerulosclerosis (FSGS) without nephrotic syndrome, giving the company the first approved medicine for the indication.
- Why it matters: This is a real label-expansion and revenue event, not just a clinical headline. FILSPARI was already commercial in IgAN; adding FSGS creates a second rare-renal franchise leg, expands the treated population and gives investors a cleaner framework for peak-sales and operating-leverage assumptions. It also strengthens the regulatory precedent for proteinuria-based kidney endpoints in specialty nephrology.
-
Source:
Reuters
- More: Company PR
|
| 3 | Regeneron enters radiopharma via Telix collaboration |
-
Regeneron and Telix agreed a radiopharma collaboration spanning four initial solid-tumor programs, with Telix receiving $40M upfront and potential milestone payments plus royalties if it opts out of the co-funding / profit-share structure.
-
Why it matters:
This is external pipeline building into one of oncology’s hottest strategic categories. Radiopharma is no longer just a platform curiosity — it is becoming a capital-allocation lane for large-cap biotech and pharma. For Regeneron, the key question is whether antibody strength plus Telix manufacturing can create a differentiated, scalable franchise rather than a one-off deal.
-
Source:
Fierce Biotech
- More: Company PR
|
Everything Else that broke
- Spyre’s UC readthrough added operating context to the follow-on: management pitched the Phase 2 result as evidence SPY001 could challenge Entyvio on both efficacy and convenience. — Fierce Biotech
- FDA is narrowing its search for a new CBER leader following Vinay Prasad’s departure, a personnel move worth watching for downstream review posture across vaccines, biologics and cell & gene therapy. — Endpoints
- Allogene data suggest off-the-shelf CAR-T may delay relapse in lymphoma, a useful proof-point for the allogeneic cell-therapy risk/reward debate. — Fierce Biotech
- Boehringer and Amgen discarded separate early immunology candidates after concluding they lacked sufficient clinical potential, a clean reminder that inflammation attrition still bites early pipelines. — Fierce Biotech
- Novo Nordisk and OpenAI unveiled a broad AI partnership spanning discovery, development and commercial operations. — Reuters
- Click Therapeutics cut 27% of staff after a recent $50M raise, reinforcing how uneven digital-therapeutics financing remains even after capital is secured. — Endpoints
- Seer confirmed an unsolicited proposal and dissident director nominations from the Radoff-JEC Group. — PR
- Kelun-Biotech posted Phase 2 sacituzumab tirumotecan data at SGO, keeping ADC competition in gyn-onc on the radar. — PR
Deal Flow
| BioBucks 2026 Deal Trackers • Updated weekly ⬇️
|
M&A / BD&L
-
Regeneron and Telix struck a radiopharma collaboration worth $40M upfront plus up to $2.1B in milestones, with a 50/50 co-development and profit-share option across four initial solid-tumor programs. — PR
-
Novo Nordisk and OpenAI announced a strategic partnership spanning drug discovery, development, manufacturing and commercial operations. — Reuters
-
Kazia in-licensed a first-in-class SETDB1 inhibitor drug development platform. — PR
-
BioOra and Cincinnati Children’s partnered on a next-generation CAR-T program for pediatric leukemia. — PR
VC / Private Financings
- No new notable VC / private financings identified since the last edition; Monday’s Imbria and Vivatides rounds remain the key recent financings already captured. — Fierce fundraising tracker
IPOs / Follow-Ons
- Spyre Therapeutics proposed a $300M public offering of common stock. — PR
- Kailera has now launched its IPO roadshow, marketing a roughly $528.5M deal to back a quartet of China-sourced obesity assets. — Fierce Biotech
- Alamar is also moving ahead in the IPO window, while Seaport, Hemab and Avalyn keep the biotech filing queue active behind the lead names. — Reuters
Things that make you go hmmm ...
Radiopharma's new dealmaking rule: if you're not buying the factory, you're not really buying. By 2025, nearly every radiopharma transaction included a manufacturing or supply component. Regeneron got the memo — its new Telix pact is built around production access, not a pipeline acquisition. Source: Bain & Company.
Academic Corner
- Plasma proteomic signature of the human menstrual cycle. — Nature Medicine
- Endovascular Therapy for Post-Thrombotic Syndrome — A Randomized Trial. — NEJM
|
|
That’s it for today, see you tomorrow. — BioBucks Team
|
|
|
